Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C

Hepatic iron has been associated with more aggressive liver disease in chronic viral hepatitis. We evaluated whether the recently described C282Y mutation of the hemochromatosis gene, designated HFE (responsible for at least 83% of hereditary hemochromatosis), was associated with more advanced liver disease in chronic hepatitis C. One hundred thirty‐seven patients with biopsy‐proven chronic hepatitis C were studied and liver biopsies scored for necroinflammation (grade 0‐18) and fibrosis (stage 0‐6). Genomic DNA was amplified by polymerase chain reaction and the C282Y mutation identified by restriction with RsaI and electrophoretic separation of restriction fragments. Ten (7.3%) patients had the C282Y mutation. No C282Y homozygous patients were identified. Age, sex distribution, and estimated weekly alcohol consumption were not significantly different between those with and without the mutation. Serum ferritin was higher in the heterozygotes (mean, 339 μg/L) compared with homozygous wild types (153 μg/L; P = .0005). In the majority of patients, liver iron was graded 0 out of 4, but hepatocyte iron staining was more commonly present in heterozygotes compared with homozygous normals (30% compared with 4% [P = .02]). Liver disease was more advanced in those with the mutant allele (mean fibrosis stage: 3.6, compared with wild type: 1.5 [P = .01]). Cirrhosis was found more often in those with the mutation (40%) compared with those without (8.7%) (P = .01; odds ratio: 7.6 [1.9‐31.2]). There was no significant difference in inflammation scores between heterozygotes and wild type (mean, 5.4 compared with 4.1). Hepatitis C virus (HCV)‐RNA titers were measured by branched DNA assay (HCV RNA 2.0‐Chiron), and there was no difference between heterozygous and homozygous normal patients. Thus, despite relatively minor increases in iron stores, individuals who are heterozygous for hemochromatosis appear to develop more fibrosis in chronic hepatitis C. Venesection may be useful therapy in this subgroup.

[1]  Roger Williams,et al.  A simple genetic test identifies 90% of UK patients with haemochromatosis , 1997, Gut.

[2]  H. Imamura,et al.  Long‐term consequence of rat orthotopic liver transplantation with and without hepatic arterial reconstruction: A clinical, pathological, and hemodynamic study , 1997, Hepatology.

[3]  R. Wolff,et al.  The Hemochromatosis Founder Mutation in HLA-H Disrupts β2-Microglobulin Interaction and Cell Surface Expression* , 1997, The Journal of Biological Chemistry.

[4]  J. Ludwig,et al.  Hemosiderosis in cirrhosis: a study of 447 native livers. , 1997, Gastroenterology.

[5]  J. Bodmer,et al.  Putting a hold on ‘HLA–H’ , 1997, Nature Genetics.

[6]  A. Rothman,et al.  Iron and chronic viral hepatitis , 1997, Hepatology.

[7]  E. Beutler.  Genetic irony beyond haemochromatosis: clinical effects of HLA-H mutations , 1997, The Lancet.

[8]  M. Worwood,et al.  Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda , 1997, The Lancet.

[9]  M. Worwood,et al.  The frequency of hemochromatosis‐associated alleles is increased in British patients with sporadic porphyria cutanea tarda , 1997, Hepatology.

[10]  L. Jorde,et al.  Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. , 1996, The New England journal of medicine.

[11]  R. Kirsch,et al.  Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C. , 1996, Journal of hepatology.

[12]  C. P. Morris,et al.  Haemochromatosis and HLA–H , 1996, Nature Genetics.

[13]  P. Fergelot,et al.  Haemochromatosis and HLA–H , 1996, Nature Genetics.

[14]  H. Bonkovsky,et al.  An update on iron metabolism: Summary of the Fifth International Conference on Disorders of Iron Metabolism , 1996, Hepatology.

[15]  M. C. Ellis,et al.  A novel MHC class I–like gene is mutated in patients with hereditary haemochromatosis , 1996, Nature Genetics.

[16]  A. Pezzoli,et al.  Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. , 1996, Journal of hepatology.

[17]  S. Fargion,et al.  Liver iron concentration in chronic viral hepatitis: a study of 98 patients , 1995, European journal of gastroenterology & hepatology.

[18]  S. Seki,et al.  Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis , 1995, The Lancet.

[19]  P. Brissot,et al.  Reduction of liver iron content following tratment of chronic hepatitis C , 1995 .

[20]  M. Kikuyama,et al.  Hepatic lipid peroxidation in chronic hepatitis C , 1995 .

[21]  G. Brittenham,et al.  Experimental liver cirrhosis induced by alcohol and iron. , 1995, The Journal of clinical investigation.

[22]  K. Ishak,et al.  Histological grading and staging of chronic hepatitis. , 1995 .

[23]  M. Tong,et al.  Clinical outcomes after transfusion-associated hepatitis C. , 1995, The New England journal of medicine.

[24]  E. Schiff,et al.  Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. , 1995, Gastroenterology.

[25]  A. Floreani,et al.  Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. , 1995, Journal of hepatology.

[26]  M. Yano,et al.  Serum aminotransferase levels as an indicator of the effectiveness of venesection for chronic hepatitis C. , 1995, Journal of hepatology.

[27]  D. V. van Thiel,et al.  Iron reduction therapy: simply camouflage, or a real weapon? , 1994, The American journal of gastroenterology.

[28]  A. Dabbagh,et al.  The effect of iron overload on rat plasma and liver oxidant status in vivo. , 1994, The Biochemical journal.

[29]  B. Bacon.  Beneficial effect of iron reduction therapy in patients with chronic hepatitis C who failed to respond to interferon-$alpha; , 1993 .

[30]  A. Alberti,et al.  Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. , 1993, Journal of hepatology.

[31]  J. Hoofnagle,et al.  Measurements of iron status in patients with chronic hepatitis. , 1992, Gastroenterology.

[32]  K. Ishak,et al.  Long‐term clinical and histopathological follow‐up of chronic posttransfusion hepatitis , 1991, Hepatology.

[33]  C. Jacquelinet,et al.  Hepatitis B virus infection markers in genetic haemochromatosis. A study of 272 patients. , 1991, Journal of hepatology.

[34]  K. Summers,et al.  Identification of homozygous hemochromatosis subjects by measurement of hepatic iron index , 1990, Hepatology.

[35]  P. Taylor,et al.  Body iron stores and the risk of cancer. , 1988, The New England journal of medicine.

[36]  B. Bacon,et al.  Lipid peroxidation and associated hepatic organelle dysfunction in iron overload. , 1987, Chemistry and physics of lipids.

[37]  L. Weintraub,et al.  Pathogenesis of hepatic fibrosis in experimental iron overload , 1985, British journal of haematology.

[38]  E. Lustbader,et al.  Serum ferritin as a predictor of host response to hepatitis B virus infection. , 1983, Science.

[39]  E. Lustbader,et al.  Changes in serum iron levels due to infection with hepatitis B virus. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[40]  W. Irish,et al.  Response to interferon α therapy is influenced by the iron content of the liver , 1994 .

[41]  M. Failla,et al.  Liver damage in Italian patients with hereditary hemochromatosis is highly influenced by hepatitis B and C virus infection. , 1992, Journal of hepatology.

[42]  G. Lescoat,et al.  Liver fibrosis in genetic hemochromatosis. Respective roles of iron and non-iron-related factors in 127 homozygous patients. , 1992, Journal of hepatology.

[43]  Mark L. Bassett,et al.  Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis , 1986, Hepatology.

[44]  E. Weinberg.  Iron withholding: a defense against infection and neoplasia. , 1984, Physiological reviews.

[45]  Leon Schiff,et al.  Diseases of the liver , 1975 .

[46]  J. Stasney,et al.  Iron-storage disease. , 1956, Seminar.